NEW YORK – Natera has sued Progenity, alleging that the molecular diagnostics firm's noninvasive prenatal Innatal test infringes six of its patents.
The suit comes shortly after Progenity filed for an initial public offering in which it is seeking to raise up to $122.6 million.
In its complaint, filed on Wednesday with the US District Court for the Western District of Texas, Waco Division, Natera claims that the use and sale of Progenity's Innatal Prenatal Screen test infringes six of its patents: US Patents 9,228,234 and 10,522,242, both titled "Methods for noninvasive prenatal ploidy calling"; US Patents 9,424,392, 10,227,652, and 10,240,202, all titled "System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals;" and US Patent 10,266,893, titled "System and method for cleaning noisy genetic data and determining chromosome copy number."
Natera is seeking injunctive relief, monetary damages, court expenses, and a jury trial.